| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
SAB Biotherapeutics, Inc.$3.82
-0.07 (-1.77%)
C 49Pipeline Score Fair Value Biotech · Commercial
Market Cap
298.21 M
EPS
-1.00
P/E Ratio
-
Value Trade
1.11 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
13.40 M
Operating CF
-14.27 M
Total Assets
248.47 M
Total Liabilities
21.22 M
Equity
227.25 M
D/E Ratio
12,345
1.56 %
Week
1.3 %
1 Month
1.3 %
3 Month
1.3 %
6 Month
-96.03 %
5 Year
-96.18 %
All Time
Cash Data
Cash Position
107.39 M
Monthly Burn
4.76 M
Runway
20.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
296.38 K
52 Week Range
1.60 - 6.60
% held by Insiders
15.78 %
% held by Institutions
76.6 %
Enterprise Value
196.99 M
Total Shares
50.94 M
Short %
8.01 %
Float Shares
47.12 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for SAB Biotherapeutics, Inc.
290Total events
4Upcoming
65Tier-1 (high impact)
2021 – 2028Coverage
Upcoming catalysts 4
Event history 286
Jun 10, 2026
◆Poster PresentationSAB-142Presentation
Poster presentation at FOCIS 2026 Annual Meeting on positive clinical translation of a juvenile NHP study for SAB-142
type 1 diabetessource ↗
Jun 5, 2026
◆Oral PresentationSAB-142Presentation
Oral presentation at ADA 2026 Scientific Sessions on SAB-142 clinical safety, PK, immunogenicity, and PD following repeat dosing
type 1 diabetessource ↗
Apr 22, 2026
▲Oral PresentationSAB-142Presentation
Presentation of additional clinical and mechanistic data from SAB-142 Phase 1 trial at IDS 2026
type 1 diabetessource ↗
Mar 19, 2026
▼Equity OfferingCorporate
Closing of $85 million public offering of common stock and pre-funded warrants
Mar 17, 2026
▼Equity OfferingCorporate
Pricing of $85 million public offering of common stock and pre-funded warrants
Mar 11, 2026
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
Mar 10, 2026
▲Full ResultsSAB-142Clinical Data
Additional Phase 1 data for SAB-142 in established T1D cohort showing C-peptide preservation
type 1 diabetessource ↗
Mar 10, 2026
▲Enrollment UpdateSAB-142Trial
SAFEGUARD trial enrolling and dosing participants
type 1 diabetessource ↗
Mar 9, 2026
Feb 25, 2026
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
Feb 11, 2026
◆Oral PresentationPresentation
Guggenheim Securities Emerging Outlook: Biotech Summit Fireside Chat
Drug Pipeline Intelligence
C49
Pipeline Score $463M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.6x
rNPV / MCap Top 73%
Micro Cap (rank 247 of 911)
Percentile RankSAB Biotherapeutics, Inc. carries a moderate pipeline score (49/100), with $3.6B risk-adjusted pipeline value, led by High Dose SAB-142 in Type 1 Diabetes (Phase 2), across $75B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAB-142 Small molecule | Type 1 Diabetes (T1D) | Phase 3 | NCT07670650 | 53% | $2.5B | NOT YET_RECRUITING | 108 | - | - | Sep 1, 2030 | - | LOW Jun 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SAB-142 | autoimmune Type 1 Diabetes | Phase 1 | 2026-04-22 | All 4 T1D participants receiving SAB-142 showed C-peptide preservation; 3 of the 4 participants showing a super responder profile; improved glycemic control vs baseline based on continuous glucose monitoring (CGM) time in range data Read More | SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 All 4 T1D participants receiving SAB-142 showed C-peptide pre Read More | |
SAB-142 | autoimmune Type 1 Diabetes | Phase 1 | 2026-04-22 | All 4 T1D participants receiving SAB-142 showed C-peptide preservation; 3 of the 4 participants showing a super responder profile; improved glycemic control vs baseline based on continuous glucose monitoring (CGM) time in range data Read More | SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 All 4 T1D participants receiving SAB-142 showed C-peptide pre Read More | |
SAB-142 | autoimmune Type 1 Diabetes | Phase 1 | 2026-04-22 | All 4 T1D participants receiving SAB-142 showed C-peptide preservation; 3 of the 4 participants showing a super responder profile; improved glycemic control vs baseline based on continuous glucose monitoring (CGM) time in range data Read More | SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 All 4 T1D participants receiving SAB-142 showed C-peptide pre Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SABS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SABS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SABSSAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
SAB Biotherapeutics, Inc. announced it will present data on SAB-142 at the American Diabetes Association's 2026 Scientific Sessions and the FOCIS 2026 Annual Meeting. The presentations will highlight the clinical safety and efficacy of SAB-142, a promising immunotherapy for newly diagnosed Stage 3 type 1 diabetes patients. The company aims to advance its ongoing Phase 2b SAFEGUARD study.
Read more →SABSSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
SAB Biotherapeutics, Inc. will release its first quarter 2026 financial results on May 12, 2026. A conference call and webcast will be held at 8:30 AM ET to discuss these results and provide business updates. The company is focused on developing treatments for autoimmune diseases, including its lead candidate SAB-142 for type 1 diabetes.
Read more →SABSSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 All 4 T1D participants receiving SAB-142 showed C-peptide pre
SAB Biotherapeutics presented promising data on their Phase 1 trial of SAB-142 for treating autoimmune Type 1 Diabetes at the IDS 2026 Congress. All four participants receiving SAB-142 demonstrated preserved C-peptide levels, with three exhibiting a super responder profile. The treatment also led to improved glycemic control, indicating its potential effectiveness without increasing insulin use. This data supports the idea of SAB-142 as a promising long-term immunotherapy for patients with established T1D.
Read more →SABSSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics has successfully closed an $85 million public offering, selling over 19 million shares of common stock and pre-funded warrants. The proceeds will primarily fund the continued development of its lead candidate, SAB-142, aimed at treating type 1 diabetes. The offering was managed by notable investment banks, enhancing its credibility.
Read more →SABS▼ -9.1%on this newsshared move
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc. has announced the pricing of an $85 million public offering of common stock and pre-funded warrants. The offering includes 19,324,677 shares at $3.85 each, with additional options for underwriters. Proceeds will primarily fund the development of SAB-142 for type 1 diabetes and other operational needs. The offering is expected to close on March 19, 2026, pending customary conditions.
Read more →SABSSAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants MIAMI
SAB Biotherapeutics, Inc. has announced a proposed public offering of its common stock and pre-funded warrants as part of its efforts to fund the continued development of SAB-142, a treatment for type 1 diabetes and other autoimmune diseases. The company plans to use the funds for clinical trials, manufacturing, regulatory, and operational activities. The offering includes a 30-day option for underwriters to purchase additional shares. Market and other conditions may affect the completion and size of the offering.
Read more →SABS▲ +6.8%on this news· ran to +19% by day 1
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller,
SAB Biotherapeutics announced promising Phase 1 data for SAB-142, a treatment aimed at Type 1 Diabetes (T1D). The trial, which included adult patients with established T1D, showed early signs of C-peptide preservation in treated participants, suggesting a potential disease-modifying effect. A key opinion leader, Michael J. Haller, commented on the encouraging nature of the data, which aligns with the expected therapeutic mechanism. The Company is advancing SAB-142 into a more extensive Phase 2b trial called SAFEGUARD, focusing on evaluating safety and efficacy in new-onset T1D patients.
Read more →SABSSAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc. (SABS) announced its participation in two upcoming investor conferences in March 2026. The conferences include the Leerink Partners Global Healthcare Conference and the Barclays 28th Annual Global Healthcare Conference, both taking place in Miami Beach, FL. The company is focused on developing hATG for type 1 diabetes and other autoimmune diseases.
Read more →SABS▼ -5.9%on this news
SAB BIO to Participate in Upcoming February 2026 Investor Conferences
SAB Biotherapeutics, Inc. (Nasdaq:SABS) announced its participation in two investor conferences in February 2026. The events include the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. These conferences will feature fireside chats with the company's management team, highlighting their advancements in developing treatments for type 1 diabetes and other autoimmune diseases.
Read more →SABS▲ +9.7%on this news
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB Biotherapeutics has appointed David Zaccardelli, Pharm.D., as Chair of the Board and Rita Jain, M.D., as an Independent Director. Both appointments are effective immediately and are expected to enhance the company's strategic direction. Zaccardelli brings extensive biotech experience, while Jain specializes in autoimmune disease drug development. Their leadership is anticipated to significantly impact SAB BIO's growth and clinical advancements.
Read more →SABSThe material in this presentation has been prepared by SAB Biotherapeutics, Inc., doing business as SAB BIO (“SAB”) and is general background information about SAB's activities current as of the date of thi
SAB Biotherapeutics, Inc. (SAB) has provided a corporate presentation highlighting its ongoing developments in transforming treatment for Type 1 Diabetes (T1D). The company is currently conducting a registrational Phase 2b SAFEGUARD study for its lead product candidate, SAB-142, which aims to modify the disease rather than merely treat symptoms. SAB is uniquely positioned due to its proprietary multi-specific antibody platform and solid financial backing, allowing it to advance its clinical programs and address the substantial market opportunity in autoimmune diseases. The presentation detailed the expected timeline for the SAFEGUARD study and emphasized the unmet need for effective therapies in T1D care.
Read more →SABSSAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
SAB Biotherapeutics announced positive results from a Phase 1 trial of SAB-142 for treating stage 3 type 1 diabetes (T1D). The trial confirmed the safety and pharmacodynamic activity of SAB-142, leading to its advancement into a Phase 2b clinical trial. The treatment was well-tolerated, with no serious adverse events reported.
Read more →SABS▼ -10.8%on this news
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
SAB Biotherapeutics, Inc. will present data on SAB-142 at the ATTD-Asia conference in Singapore. This immunotherapy is in Phase 2b development for delaying type 1 diabetes progression in new-onset patients. The presentations will detail SAB-142's mechanism of action and safety profile, showcasing its potential as a leading treatment option.
Read more →SABSSAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
SAB Biotherapeutics reported its third quarter financial results and highlighted significant advancements, including the initiation of the Phase 2b SAFEGUARD study for its lead candidate, SAB-142. The company activated multiple clinical trial sites globally and showcased positive Phase 1 study results at major conferences. SAB-142 aims to modify the disease progression of Stage 3 type 1 diabetes.
Read more →SABSSAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
SAB Biotherapeutics announced that it will present data on SAB-142 at the ISPAD Annual Conference. The presentations will highlight the progress of SAB-142, aimed at delaying type 1 diabetes progression in Stage 3 patients. The data supports SAB-142's potential as a leading therapy for autoimmune type 1 diabetes.
Read more →SABS▼ -11.5%on this news· ran to -23% by day 3
SAB BIO Highlights Data in Multiple Presentations at EASD
SAB Biotherapeutics announced the initiation of its Phase 2b SAFEGUARD study for SAB-142 targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients. The company presented data at the EASD Annual Meeting, emphasizing the potential of SAB-142 as a novel immunotherapeutic approach. Collaboration with INNODIA and positive results from the MELD-ATG study further validate the treatment's efficacy.
Read more →SABSSAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
SAB Biotherapeutics, Inc. will present five sessions related to its immunotherapy SAB-142 at the 2025 EASD Annual Meeting in Vienna. The presentations include an INNODIA-hosted symposium and four oral presentations focusing on the mechanism of action and pharmacokinetics of SAB-142. This event highlights SAB BIO's commitment to advancing treatments for Type 1 Diabetes.
Read more →SABSSAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
SAB BIO reported strong financial results for Q2 2025, raising $175 million through a private placement, which included strategic investor Sanofi. The funds will support the pivotal Phase 2b SAFEGUARD study for SAB-142, aimed at delaying type 1 diabetes progression. The study is set to begin in Q3 2025, following positive FDA feedback.
Read more →SABS▲ +5.1%on this news
SAB BIO Announces Oversubscribed $175 Million Private Placement
SAB BIO has announced a successful oversubscribed private placement raising $175 million, with participation from notable investors including Sanofi and RA Capital Management. The funds will be used to complete the pivotal Phase 2b SAFEGUARD study for SAB-142, aimed at delaying progression of autoimmune type 1 diabetes. The financing is expected to extend the company's cash runway into mid-2028.
Read more →SABSSAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
SAB BIO reported its Q1 2025 financial results, highlighting significant advancements in its immunotherapy platform targeting type 1 diabetes (T1D). The company noted positive topline data from its Phase 1 trial for SAB-142, which is aimed at delaying the onset of T1D. CEO Samuel J. Reich emphasized the accelerating momentum in the T1D treatment landscape.
Read more →SABS▼ -8.1%on this news· ran to -20% by day 3
SAB BIO Reports Full Year 2024 Operating and Financial Results
SAB BIO reported its financial results for the fourth quarter and full year of 2024, highlighting positive topline data for its lead asset, SAB-142, aimed at treating type 1 diabetes. The company plans to initiate a Phase 2b trial for SAB-142 and is focused on developing partnerships to advance its pipeline. CEO Samuel J. Reich expressed optimism about the company's future prospects.
Read more →SABS▼ -52.5%on this news
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB BIO announced positive topline results from a Phase 1 trial of SAB-142, an immunotherapy for type 1 diabetes (T1D). The study demonstrated safety and pharmacodynamic activity, allowing progression to Phase 2b trials. The company aims to evaluate SAB-142 in both adult and pediatric patients with new-onset T1D in 2025.
Read more →SABSSAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is pr
SAB BIO provided an update on the SAB-142 clinical trial during the European Association for the Study of Diabetes Annual Meeting. The company announced the completion of Phase 1 enrollment in healthy volunteers and is now advancing to enroll patients with type 1 diabetes. The trial results indicate that SAB-142 has not shown any serum sickness at the targeted dose of 2.5mg/kg. This novel immunotherapy aims to modify the disease progression of type 1 diabetes, with a topline data readout expected by the end of the year.
Read more →SABSSAB BIO Appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics, Inc. has appointed Lucy To as the Chief Financial Officer, effective August 12, 2024. With over 18 years of investment banking expertise, Ms. To is expected to lead the company's corporate finance and strategy. SAB anticipates top-line Phase 1 data for its lead candidate, SAB-142, targeting type 1 diabetes (T1D), by the end of 2024. Her prior experience includes roles at Wells Fargo, Deutsche Bank, and others in healthcare investment banking.
Read more →SABS▲ +7.4%on this news
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics has rebranded itself as SAB BIO to better reflect its mission in addressing unmet needs in type 1 diabetes. The company is now focusing on its lead candidate, SAB-142, which aims to modify disease progression in recent onset Stage 3 T1D patients. The rebranding includes a new name and visual identity, alongside updates to the company's website. The announcement precedes a significant presentation planned at the upcoming American Diabetes Association's Scientific Sessions in June 2024.
Read more →SABS▼ -20.6%on this newsshared move
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
SAB Biotherapeutics will present at the American Diabetes Association's 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida. The presentation will focus on SAB-142, a novel human anti-thymocyte immunoglobulin aimed at delaying the progression of type 1 diabetes. This innovative therapy is designed to preserve insulin-producing beta cells by modulating the immune response. The event will gather leading diabetes experts and researchers, highlighting cutting-edge diabetes research and treatment advancements.
Read more →SABS▼ -6.4%on this news
SAB Biotherapeutics Announces Departure of Chief Financial Officer
SAB Biotherapeutics announced the departure of Chief Financial Officer Michael King, who is moving on to become CEO of a privately-held oncology company. King will continue to serve as an advisor to SAB until the end of the year, while the Board of Directors initiates a search for a new CFO. Mark Conley, currently Vice President of Finance, will assume the role of Interim CFO. The company remains focused on its growth and clinical program for type 1 diabetes and confirmed its fiscal outlook for 2024.
Read more →SABS▼ -15.7%on this news
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
SAB Biotherapeutics announced that the FDA has cleared their IND application for SAB-142, enabling its clinical trial for type 1 diabetes. This development allows enrollment of patients in their phase 1 HUMAN trial, which aims to assess the safety and efficacy of SAB-142. The therapy seeks to modify the immune response to preserve insulin-producing beta cells. The trial will establish important pharmacokinetic and pharmacodynamic profiles, potentially changing treatment approaches for T1D.
Read more →SABSSAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
SAB Biotherapeutics has announced its financial results for the first quarter of 2024, highlighting a net loss of $4.0 million and increased research expenses. The company remains optimistic about its immunotherapy platform targeting type 1 diabetes (T1D) and has successfully enrolled the third cohort for its lead candidate, SAB-142. Key leadership changes, including the appointment of Dr. Jay Skyler to the Board, are expected to enhance the company’s focus on T1D. SAB has adequate cash reserves to fund its operations through 2026.
Read more →SABSSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors MIAMI
SAB Biotherapeutics has announced the appointment of Dr. Jay Skyler to its Board of Directors. Dr. Skyler brings over five decades of experience in type 1 diabetes research, which is expected to provide valuable insights for the company's disease-modifying therapy program, specifically SAB-142. This therapy aims to delay the onset of type 1 diabetes by targeting immune cells that attack insulin-producing beta cells, presenting a potential shift in treatment paradigms. SAB is optimistic about the implications of this addition to its leadership and the advancements in its therapeutic approach.
Read more →SABS▲ +5.9%on this news
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics has announced the completion of dosing for the third cohort in the Phase 1 trial of SAB-142, an innovative human immunoglobulin targeting type 1 diabetes. Conducted with no reported cases of serum sickness, the trial aims to evaluate the safety, tolerability, and biological activity of this treatment. With regulatory approval received in October 2023, SAB-142 represents a significant advancement over traditional rabbit anti-thymocyte globulin (ATG) treatments by offering a human alternative designed to mitigate immune response risks. This therapy aims to delay disease onset and progression in patients with type 1 diabetes.
Read more →SABSSAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics, Inc. is set to present at the INNODIA Annual Meeting in Leuven, Belgium, where Chief Medical Officer Dr. Alexandra Kropotova will discuss the clinical development plan for SAB-142, aimed at delaying type 1 diabetes progression. The partnership with INNODIA enhances access to top-tier clinical trial sites and expertise. Dr. Kropotova emphasized the urgent need for disease-modifying therapies for type 1 diabetes and the collaborative efforts to advance their clinical programs.
Read more →SABSSAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
SAB Biotherapeutics announced that its CEO, Samuel J. Reich, will present at the Needham Virtual Healthcare Conference on April 11, 2024. The presentation will focus on the company's lead clinical program, SAB-142, which is being developed to delay the onset and progression of type 1 diabetes. SAB Biotherapeutics employs advanced genetic engineering to produce human IgGs without human donors, setting a new standard in immunotherapy. The conference will also feature virtual 1:1 meetings and a replay of the presentation will be available on the company's website for one year.
Read more →SABS▼ -5.5%on this newsshared move
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
SAB Biotherapeutics announced its full year 2023 financial results, highlighting a net loss of $42.2 million. The company has successfully pivoted to focus on its lead asset, SAB-142, which is on track for Phase 1 trial data release in 2024. It secured up to $110 million in financing, which, along with existing cash reserves, is expected to fund operations into 2026. New appointments to the board aim to strengthen the company's strategic focus on treating Type 1 diabetes.
Read more →SABS▼ -12.9%on this news
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
SAB Biotherapeutics has entered a clinical partnership with the Navy Medical Research Center to study SAB-176, a potential treatment for influenza types A and B. This safety and tolerability study will be conducted on healthy volunteers and is funded by the Henry Jackson Foundation. SAB-176, which utilizes the company’s DiversitAb platform, has already received Breakthrough Therapy and Fast Track Designations from the FDA based on prior positive clinical data. The study aims to explore a new administration method that could enhance the delivery of this promising therapeutic product.
Read more →SABSSAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SAB Biotherapeutics announced that its CEO, Samuel J. Reich, will present at the BIO CEO & Investor Conference on February 26, 2024. The presentation will focus on the company's lead asset, SAB-142, which is aimed at delaying the onset and progression of Type 1 diabetes. The conference is a notable event for institutional investors and industry analysts in biotechnology. SAB Biotherapeutics aims to revolutionize treatment techniques without relying on human donors for its therapeutic products.
Read more →SABSSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAB Biotherapeutics, Inc. is set to present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. CEO Samuel J. Reich will provide an overview of the company and its lead clinical program, SAB-142, which aims to delay the onset and progression of type 1 diabetes. This presentation offers a platform to share the latest developments and innovations related to the company's immunotherapy platform. The webcast of the event will be accessible on the company's website post-presentation.
Read more →SABSSAB Biotherapeutics Announces Executive Leadership Change
SAB Biotherapeutics has announced an executive leadership change as Samuel J. Reich steps up from Executive Chairman to Chief Executive Officer, effective February 2, 2024. Eddie J. Sullivan will retain his position as President, overseeing operations and research. This leadership shift aims to better align the company with its strategic goals, particularly around its lead product candidate, SAB-142, which targets type 1 diabetes. Both executives express optimism about the company's direction and potential milestones for the upcoming year.
Read more →SABSSAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has announced that it has regained compliance with Nasdaq's minimum bid price requirement. This compliance follows a reverse stock split conducted on January 5, 2024, aimed at increasing the share price above the $1.00 threshold. After maintaining the required bid price for at least 10 consecutive business days, the company has now fulfilled Nasdaq's listing standards as of January 23, 2024.
Read more →SABSForward-Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (“SAB”) and is general background information about SAB's activities current as of the date of t
SAB Biotherapeutics has introduced a fully human anti-thymocyte biologic, SAB-142, aimed at preventing Type 1 diabetes. The company is conducting a First-In-Man (FIM) study for this treatment, with Phase 1 data anticipated by the end of 2024. The therapeutic approach has garnered support from the Juvenile Diabetes Research Foundation and shows promising potential in addressing recent onset Type 1 diabetes. As screening programs expand, SAB-142 is positioned to fill a significant gap in the existing treatment options for this condition.
Read more →SABSSAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
SAB Biotherapeutics has announced a 1-for-10 reverse stock split effective January 5, 2024, to comply with Nasdaq's minimum share price listing requirement. The split will reduce the number of its outstanding shares from approximately 92.25 million to around 9.225 million, without affecting the total value of ownership for shareholders. The stock split has been approved by stockholders and will be reflected in trading as the adjusted stock price begins, aiming to improve market perception and share price stability.
Read more →SABS▼ -5.4%on this news
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes First subject has been dosed in the first-in-man Phase 1 clinical s
SAB Biotherapeutics has announced the initiation of a Phase 1 clinical trial for SAB-142, a fully-human anti-thymocyte immunoglobulin aimed at modifying the disease progression of Type 1 Diabetes. The trial, which is being conducted in Australia, will assess the safety, tolerability, and pharmacokinetics of the treatment in both healthy volunteers and participants with Type 1 Diabetes. The company plans to file for Investigational New Drug application with the U.S. FDA and other regulatory bodies in 2024 to advance to Phase 2b studies, marking a key milestone in their drug development efforts.
Read more →SABSSAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
SAB Biotherapeutics has appointed Katie Ellias to its Board of Directors, enhancing its leadership team as it advances its immunotherapy platform targeting type 1 diabetes. Mrs. Ellias brings substantial experience from her previous roles, including managing investments at the JDRF T1D Fund, where she focused on therapies for diabetes. As the board now consists of ten members, with a strong representation of independent directors, the company expresses confidence in its future growth and strategic direction in the T1D treatment space.
Read more →SABSSAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
SAB Biotherapeutics has successfully secured $67.1 million in financing to support the development of SAB-142, a potential disease-modifying treatment for type 1 diabetes. This funding will sustain the program through its Phase 1 clinical trial, which aims to evaluate the therapy's ability to preserve insulin-producing beta cell function. The funding round saw support from notable investors, reflecting strong confidence in the therapy's potential to address unmet medical needs in the diabetes treatment paradigm. With recent regulatory approval, SAB-142 is positioned to begin trials assessing its efficacy as a fully-human immunotherapy.
Read more →SABSSAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
SAB Biotherapeutics announced its Q3 2023 financial results, highlighting a successful $67.1 million fundraising through private placements and received approval to begin a Phase 1 clinical trial for its lead candidate, SAB-142, targeting type 1 diabetes. The company has appointed Michael G. King Jr. as CFO and shows confidence in sustaining operations through 2026. However, its net loss for Q3 increased, raising concerns about financial sustainability amid decreasing R&D expenditures.
Read more →SABSSAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
SAB Biotherapeutics, a clinical-stage biopharmaceutical firm, announced its participation in the 35th Annual Piper Sandler Healthcare Conference from November 28 to November 30, 2023. Dr. Eddie J. Sullivan, the company's CEO, will present on November 29, discussing the firm's pioneering work in fully-human immunotherapy targeting type 1 diabetes. This platform aims to delay disease onset and prevent progression utilizing advanced genetic engineering techniques.
Read more →SABSSAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
SAB Biotherapeutics has appointed Michael G. King Jr. as Chief Financial Officer, effective October 30, 2023. He brings over 25 years of experience in the biotechnology sector and is expected to play a crucial role in the company’s strategic goals, particularly in developing treatments for type 1 diabetes. King replaces Russell Beyer, who leaves on November 15 but will remain as an advisor. Both SAB's leadership and King have expressed optimism regarding the company's future and its mission to address unmet needs in autoimmune disorders.
Read more →SABS▲ +28.5%on this news· ran to +58% by day 3shared move
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
SAB Biotherapeutics has received approval from the Australian Human Research Ethics Committee to start a Phase 1 clinical trial for SAB-142, a novel disease-modifying therapy for type 1 diabetes. This first-in-human trial aims to evaluate the safety, tolerability, and pharmacokinetics of SAB-142, a fully-human anti-thymocyte immunoglobulin. The company is also looking to file an Investigational New Drug application with the U.S. FDA to initiate trials in the United States, highlighting the growing global demand for effective treatments for type 1 diabetes.
Read more →SABSSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
SAB Biotherapeutics has appointed Andrew Moin to its Board of Directors, enhancing its governance as it advances its immunotherapy efforts for type 1 diabetes. The company has also successfully issued Series A-1 Preferred Stock, securing approximately $7.5 million as part of a larger $130 million private financing effort. The appointment of Moin, who brings significant experience in investment and a commitment to diabetes awareness, is expected to benefit the advancement of SAB-142 through clinical trials. This funding is aimed at progressing the company's lead therapeutic candidate, which has shown promise in tackling the challenges of type 1 diabetes.
Read more →SABSSAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes Funding to support clinical advancement of SAB-142, a potential disease-modifying tr
SAB Biotherapeutics has announced a private placement of up to $130 million to fund the clinical advancement of SAB-142, its lead drug candidate for Type 1 Diabetes (T1D). The financing, led by RA Capital Management along with other investors, is intended to support the company's shift towards a disease-modifying therapy for T1D, with anticipated clinical trials commencing in Q4 2023. SAB-142 aims to preserve pancreatic function and disrupt T1D progression by employing fully-human immunotherapeutic strategies.
Read more →SABSSAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
SAB Biotherapeutics announced its financial results for Q2 2023, showing a focus on advancing its immunotherapy pipeline, particularly the SAB-142 program aimed at treating Type 1 Diabetes. The company highlighted significant progress made, including positive safety data for SAB-142 and FDA designations for SAB-176. Despite these advancements, the financial results revealed an increased net loss and a decrease in cash reserves, emphasizing ongoing challenges as the company navigates its operations in a dynamic medical landscape.
Read more →SABSSAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
SAB Biotherapeutics presented encouraging results from a GLP toxicology study for SAB-142, a novel immunotherapeutic for Type 1 Diabetes, at the FOCIS 2023 conference. The study confirmed that SAB-142 is well-tolerated and effectively modulates immune cells associated with T1D, similar to existing treatments. SAB aims to file for Investigational New Drug status and commence Phase 1 clinical trials, responding to the significant need for effective disease-modifying treatments in managing T1D.
Read more →SABSSAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics announced that Dr. Eddie J. Sullivan will present positive data on their influenza treatment, SAB-176, at the BIO 2023 International Convention. The presentation will highlight recent achievements, including Breakthrough Therapy and Fast Track designations from the FDA. SAB's proprietary DiversitAb platform, which utilizes genetically modified bovines to produce fully-human antibodies, underpins their therapeutic strategies. Additionally, the company is seeking out-licensing and partnership opportunities for both SAB-176 and SAB-185, a potential COVID-19 treatment demonstrating promising Phase 3 results.
Read more →SABSSAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
SAB Biotherapeutics is set to host its Virtual 2023 R&D Day on June 14, 2023, where it will update on its innovative immunotherapy platform, DiversitAb™. The company has received Breakthrough Therapy and Fast Track designations for its SAB-176 candidate targeting influenza. Additional presentations will include data on SAB-142, a therapeutic candidate for Type 1 diabetes. This event aims to showcase the advancements in the development of fully-human polyclonal antibodies using their proprietary technology.
Read more →SABS▼ -11.4%on this newsshared move
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
SAB Biotherapeutics has reported its financial results for Q1 2023, highlighting key advancements in its immunotherapy initiatives. The company received Breakthrough Therapy and Fast Track designations for its SAB-176 treatment aimed at influenza and presented promising data from clinical trials for both SAB-176 and SAB-185. However, SAB also acknowledged a net loss of $7.3 million for the quarter, reflecting ongoing challenges in its commercial operations. Despite these challenges, the company is committed to advancing its product pipeline and strategies.
Read more →SABSSAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
SAB Biotherapeutics has announced the first publication of nonclinical data for its antibody candidate SAB-183, which shows strong immune protection against Yersinia pestis, the cause of pneumonic plague. Conducted in collaboration with the U.S. Army's research institute, the study highlights the utility of fully-human immunoglobulins produced from transchromosomic bovines. These findings suggest that SAB-183 may offer broad protective capabilities against bacterial infections, especially concerning the rise of drug-resistant strains. This publication marks a significant milestone for SAB-183 as a viable therapeutic option for serious biothreats.
Read more →SABS▼ -6.2%on this newsshared move
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
SAB Biotherapeutics has announced significant progress in the U.S. FDA's phased review of its DiversitAb platform, achieving approval for five out of seven necessary sections of the New Animal Drug Application (NADA). This platform enables the production of fully-human polyclonal antibodies without human donors. The company is poised to complete the remaining sections of the NADA, which will help in pursuing Biologics License Applications (BLAs) for its investigational drugs. Additionally, SAB has received regulatory designations for some treatments, indicating a strong pipeline for addressing various unmet medical needs.
Read more →SABSSAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
SAB Biotherapeutics presented positive Phase 1 and 2a clinical trial data for its influenza immunotherapy SAB-176 at the ISIRV-AVG conference. The results indicate that SAB-176 is safe, well-tolerated, and effective in reducing viral load in high-risk patients. Additionally, the treatment has received Breakthrough Therapy and Fast Track designations from the FDA, underscoring its significance in managing influenza, especially in vulnerable populations. The presentation highlighted the innovative nature of SAB-176's fully-human antibody approach alongside promising findings from combination preclinical studies.
Read more →SABSSAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Dr. Eddie Sullivan, will present at the Sidoti Virtual Investor Conference on May 10-11, 2023. The presentation will cover the company's immunotherapy platform and discuss new data related to its COVID-19 drug SAB-185 and the Fast-Track Designation for SAB-176 targeting influenza. Investors can register for the presentation and one-on-one meetings to learn more about the company's developments and future potential.
Read more →SABS▼ -6.9%on this news
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
SAB Biotherapeutics announced positive results from its Phase 3 trial of SAB-185, a treatment for high-risk COVID-19 patients. The trial showed that patients receiving SAB-185 experienced better symptom resolution compared to those treated with the monoclonal antibody REGEN-COV®. However, the study's primary endpoint regarding hospitalizations and deaths remains inconclusive due to insufficient clinical events, leading to the trial's halt. The data further support the effectiveness of SAB's immunotherapy platform, which does not require human donors.
Read more →SABS▲ +41.6%on this news
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
SAB Biotherapeutics has announced that the FDA has granted its investigational therapy, SAB-176, both Breakthrough Therapy and Fast Track designations. These designations indicate the potential of SAB-176 to significantly improve treatment for Type A and B influenza, especially in high-risk patients. The therapy employs a proprietary platform designed to produce fully-human multi-epitope binding antibodies, which can effectively neutralize various strains of the virus. SAB-176 is expected to advance into a Phase 2b clinical trial focused on efficacy and safety amidst ongoing global health challenges posed by influenza.
Read more →SABS▲ +99.7%on this news· ran to +187% by day 3shared move
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
SAB Biotherapeutics has received Fast Track designation from the FDA for its investigational therapeutic, SAB-176, aimed at preventing severe outcomes in high-risk influenza patients. This designation will speed up the development and review of SAB-176, which has demonstrated its effectiveness against various influenza strains. The drug utilizes SAB's proprietary DiversitAb platform, allowing for rapid production of fully-human antibodies targeting multiple virus epitopes. Clinical testing has indicated promising results for SAB-176 in terms of efficacy and safety, particularly for patients with antiviral-resistant strains.
Read more →SABSSAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
SAB Biotherapeutics has appointed Erick Lucera, CFA, to its Board of Directors, effective April 4, 2023. Lucera brings over thirty years of experience in the biotechnology and medical device industries, having previously served as CFO at AVEO Oncology. His appointment is seen as a positive step for SAB as it advances its drug development programs, particularly in immune and autoimmune disorders. Executives at SAB express confidence in Lucera's ability to contribute to the company's success.
Read more →SABS▲ +5.1%on this newsshared move
SAB Biotherapeutics Provides Company Update for Full Year 2022
SAB Biotherapeutics provided a comprehensive update on its progress for the full year 2022, highlighting significant advancements in its proprietary immunotherapy platform and the development of new treatments for various diseases. The company reported key milestones in its type 1 diabetes program, its investigational product for C. diff, and promising clinical trial results for influenza and COVID-19 treatments. Despite the positive developments, SAB announced a delay in its Form 10-K filing due to a financial restatement from 2021, which requires further review but is not expected to affect income figures. Overall, the company's future outlook appears cautiously optimistic as it seeks to address unmet medical needs and enhance patient outcomes.
Read more →SABSSAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, announced that CEO Eddie Sullivan will present at the 2023 BIO CEO & Investor Conference in New York City. His presentation will focus on the company's unique DiversitAb platform that produces fully-human polyclonal antibodies. The platform is being explored for treatment in multiple areas, including infectious diseases and autoimmune disorders. The conference offers an opportunity for innovation and collaboration among industry leaders.
Read more →SABSSAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
SAB Biotherapeutics has secured an additional $8.2 million from the U.S. Department of Defense, finalizing a total of $16.8 million from a previously discontinued COVID-19 contract. This funding supports the advancement of their novel polyclonal antibody platform, which is now in Phase 3 development. CEO Eddie Sullivan highlighted the ongoing progress of their various therapeutic programs, including for Influenza, C. diff., and Type 1 Diabetes. The company also expressed confidence in its financial position through 2023.
Read more →SABSSAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes Study shows SAB's fully-human polyclonal therapeutic that has potential to delay the
SAB Biotherapeutics announced the successful conclusion of an IND-enabling GLP toxicology study for SAB-142, an innovative immunotherapeutic aimed at delaying the onset and progression of type 1 diabetes. The study demonstrated that SAB-142 is well tolerated and exhibits a favorable pharmacologic effect at various doses. With the study's completion, the company plans to submit an IND filing within approximately 12 months, marking a significant milestone for this potential therapy.
Read more →SABS▲ +11.5%on this newsshared move
SAB Biotherapeutics' CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
SAB Biotherapeutics announced that its CMO, Dr. Alexandra Kropotova, will present at the Biotech Showcase in San Francisco. The presentation will focus on 'Next Generation Biologics in Immunology', highlighting the company's innovative DiversitAb platform. This unique platform enables the production of fully-human polyclonal antibodies, which have shown promise in clinical trials for various complex diseases. The event will provide opportunities for potential partnerships and collaborations with interested parties.
Read more →SABSSAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
SAB Biotherapeutics announced that its DiversitAb platform can generate functional, fully-human anti-idiotype polyclonal antibodies to target harmful auto-antibodies associated with autoimmune diseases. This development, in collaboration with CSL, shows promise for creating effective therapies for conditions like neuromyelitis optica and systemic lupus erythematosus. The platform's ability to produce targeted antibodies without relying on human donors signifies a significant advance in treating complex autoimmune disorders. SAB's CEO highlighted the importance of this technology in addressing unmet medical needs in the autoimmune space.
Read more →SABS▼ -6.1%on this news· ran to -17% by day 3
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the n
Read more →SABS▼ -6.4%on this news
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock SIOUX FALLS, S.D., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targete
Read more →SABS▼ -9.2%on this news
Experienced Management Team Christoph Bausch, PhD, MBA EVP & CHIEF OPERATING OFFICER 20+ years research and discovery, biomanufacturing, business development, and platform technology commercialization MilliporeSigma (Mer
ADVANCING A POWERFUL NEW CLASS OF IMMUNOTHERAPEUTIC ANTIBODIES November 2022 2022 SAB BIOTHERAPEUTICS, INC. EXHIBIT 99.1 Experienced Management Team Christoph Bausch, PhD, MBA EVP & CHIEF OPERATING OFFICER 20+ years research and discovery, biomanufacturing, business development,
Read more →SABS▼ -9.2%on this news
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
SIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need f
Read more →SABS▼ -15.2%on this news
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for
Read more →SABS▲ +8.7%on this news
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
SIOUX FALLS, S.D., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need f
Read more →SABS▲ +8.3%on this newsshared move
Forward Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (SAB) and is general background information about SAB's activities current as of the date of this presentation
Plasma Fractionation and Downstream Processing of Human Polyclonal Antibodies from the DiversitAb Platform 2022 SAB BIOTHERAPEUTICS, INC. Plasma Product Biotechnology Conference 2022 Christoph Bausch, PhD, Chief Operating Officer EXHIBIT 99.1 Forward Looking Statements 2 The mat
Read more →SABSSAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
SIOUX FALLS, S.D., Nov. 03, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need f
Read more →SABS▲ +6.3%on this news· ran to +22% by day 3
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions SIOUX FALLS, S.D. and GAITHERSBURG, MD
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions SIOUX FALLS, S.D. and GAITHERSBURG, MD, October 27, 2022 (GLOBE NEWSWIRE) SAB Biotherapeutics (Nasdaq: SABS), ( SAB ), a clinical-stage biopharmaceutical company with a novel immunother
Read more →SABSSAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
SIOUX FALLS, S.D., Sept. 28, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need
Read more →SABSSAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants
SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need
Read more →SABSSAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results
SIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for
Read more →SABS▼ -7.3%on this newsshared move
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for
Read more →SABSSAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first of its kind immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the nee
Read more →SABS▼ -8.9%on this news
Forward Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (“SAB”) and is general background information about SAB's activities current as of the date of t
ADVANCING POWERFUL NEW CLASS OF IMMUNOTHERAPEUTIC ANTIBODIES July 2022 2022 SAB BIOTHERAPEUTICS, INC. CONFIDENTIAL EXHIBIT 99.1 Forward Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. ( SAB ) and is general background informa
Read more →SABS▼ -8.9%on this news
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for
Read more →SABSSAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour
SIOUX FALLS, S.D., July 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies wi
Read more →SABSLarge Animal Genetic Engineering Summit, June 2022 2022 SAB BIOTHERAPEUTICS, INC. – CONFIDENTIAL Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutic Forward Looking Statements 2 The m
Large Animal Genetic Engineering Summit, June 2022 2022 SAB BIOTHERAPEUTICS, INC. CONFIDENTIAL Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutic Forward Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutic
Read more →SABS▼ -11.3%on this newsshared move
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer SIOUX FALLS, S.D., June 6, 2022 -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifical
Read more →SABSSAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit
In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City, Utah Dr. Christoph Bausch to share early R&D updates on SAB novel platform advancement toward developing Transchromosomic (Tc)
Read more →SABSSAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later this year Sufficient cash anticipated to operate into 2023
Read more →SABSSAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May 23-26, 2022. As part of the conference, the company’s management team will particip
Read more →SABS▼ -13.8%on this news
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need fo
Read more →SABS▲ +7.1%on this news· ran to +65% by day 3
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of seasonal influenza mid
Read more →SABS▼ -39.9%on this news
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced into Phase 3 after meeting pre-specified efficacy and safety criteria SAB-185
Read more →SABS▼ -39.9%on this news
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed convalescent plasma Findings published in The Journal of Inf
Read more →SABSSAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that p
Read more →SABS▲ +11.1%on this news
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700 patients have been enrolled in the Phase 3 trial, exceeding 50% enrollment SAB-185
Read more →SABSSAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for
Read more →SABSSAB Biotherapeutics Added to NASDAQ Biotechnology Index
SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human
Read more →SABS▼ -6.4%on this newsshared move
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
FDA laboratory testing confirms SAB-185 neutralizes Omicron and other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue to show broad neutralization to viral variants SAB-185 currently being evalua
Read more →SABSSAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by DiversitAb™ platform in past two months Positive clinical results confirm that SAB’s
Read more →SABS▼ -10.2%on this news· ran to -22% by day 1
SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at
Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis additional $60.5 million from DoD in expanded scope fo
Read more →SABSshall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K") filed with the Securities and Exchange Commission (the "SEC") on
PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION terms used but not defined in this Exhibit 99.1 shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K") filed with the Securities and Exchange Commission (the "SEC") on October 2
Read more →SABSSAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a cli
Read more →SABSSAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases SAB Bio
Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases SAB Biotherapeutics (SAB) has entered into a definitive merger agree
Read more →SABSSAB Biotherapeutics and Big Cypress Merger Call Tuesday, 22 nd June 2021 SAB Biotherapeutics and Big Cypress Merger Call Tuesday, 22 nd June 2021 Opening Remarks Melissa Ullerich Chief Corporate Communications & IR Offic
Biotherapeutics and Big Cypress Merger Call Corporate Communications & IR Officer, SAB Biotherapeutics you, operator. Good morning and thank you for joining the Big Cypress/SAB Biotherapeutics joint investor conference call and webcast. In this call, we will be discussing info
Read more →SABSBig Cypress Acquisition Corp. Announces Separate Trading of its Shares of Common Stock and Redeemable Warrants Commencing
Cypress Acquisition Corp. Announces Separate Trading of its Shares of Common Stock and Redeemable Warrants Commencing February FL - February 4, 2021 - Big Cypress Acquisition Corp. (the "Company") announced that, commencing February 9, 2021, holders of the units sold in the Com
Read more →SABSBIG CYPRESS ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and
BIG CYPRESS ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Shareholders and Board of Directors Big Cypress Acquisition Corp. Opinion on
Read more →SABSBig Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering MIAMI, FL
Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering FL - January 11, 2021 - Big Cypress Acquisition Corp. (the "Company") announced today the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. The units will
Read more →Competitive Position
How SABS ranks across every disease it competes inCompetitive Position is a premium feature
See how SABS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial